Initial levels of organ failure, microbial findings and mortality in intensive care-treated primary, secondary and tertiary sepsis

Critical Care and Resuscitation

Volumn 17, Issue 3, 2015, Pages 174-181

  Castegren, Markus ^a,b   Jonasson, Mikaela ^a   Castegren, Sara ^a   Lipcsey, Miklós ^a   Sjölin, Jan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMAN; INCIDENCE; INTENSIVE CARE; LENGTH OF STAY; MALE; MICROBIOLOGY; MIDDLE AGED; MORTALITY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PILOT STUDY; RETROSPECTIVE STUDY; RISK FACTOR; SEPSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITAL MORTALITY; HUMANS; INCIDENCE; INTENSIVE CARE; LENGTH OF STAY; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT (HEALTH CARE); PILOT PROJECTS; RETROSPECTIVE STUDIES; RISK FACTORS; SEPSIS;

EID: 84945256655     PISSN: 14412772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-54.
2. Kaukonen KM, Bailey M, Suzuki S, et al. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA 2014; 311: 1308-16.
3. Lever A, Mackenzie I. Sepsis: definition, epidemiology, and diagnosis. BMJ 2007; 335: 879-83.
4. Castellheim A, Brekke O-L, Espevik T, et al. Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand J Immunol 2009; 69: 479-91.
5. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013; 13: 260-8.
6. Van der Poll T, Meijers JCM. Systemic inflammatory response syndrome and compensatory anti-inflammatory response syndrome in sepsis. J Innate Immun 2010; 2: 379-80.
7. Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg 1976; 184: 333-41.
8. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebocontrolled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991; 324: 429-36.
9. Fisher CJ Jr, Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994; 22: 12-21.
10. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358: 111-24.
11. Bernard GR, Vincent J-L, Laterre P-F, et al. Efficacy and safety of recombinant human activated protein c for severe sepsis. N Engl J Med 2001; 344: 699-709.
12. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366: 2055-64.
13. Fisher CJ Jr, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271: 1836-43.
14. Dellinger RP, Vincent J-L, Marshall J, Reinhart K. Important issues in the design and reporting of clinical trials in severe sepsis and acute lung injury. J Crit Care 2008; 23: 493-9.
15. de Groot B, Lameijer J, de Deckere ER, Vis A. The prognostic performance of the predisposition, infection, response and organ failure (PIRO) classification in high-risk and low-risk emergency department sepsis populations: comparison with clinical judgement and sepsis category. Emerg Med J 2014; 31: 292-300.
16. Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 1996; 125: 680-7.
17. Castegren M, Lipcsey M, Söderberg E, et al. Differences in organ dysfunction in endotoxin-tolerant pigs under intensive care exposed to a second hit of endotoxin. Shock 2012; 37: 501-10.
18. Gierer P, Hoffmann JN, Mahr F, et al. Sublethal trauma model with systemic endotoxemia for the study of microcirculatory disorders after the second hit. J Surg Res 2008; 147: 68-74.
19. Gårdlund B, Sjölin J, Nilsson A, et al. Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. J Infect Dis 1995; 172: 296-301.
20. Charles PE, Ladoire S, Snauwaert A, et al. Impact of previous sepsis on the accuracy of procalcitonin for the early diagnosis of blood stream infection in critically ill patients. BMC Infect Dis 2008; 8: 163.
21. Kox WJ, Bone RC, Krausch D, et al. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch Intern Med 1997; 157: 389-93.
22. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-55.
23. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
24. Moreno R, Vincent JL, Matos R, et al. The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM. Intensive Care Med 1999; 25: 686-96.
25. Skrupky LP, Kerby PW, Hotchkiss RS. Advances in the management of sepsis and in the understanding of key immunologic defects of the disorder. Anesthesiology 2011; 115: 1349-62.
26. Kalb TH, Lorin S. Infection in the chronically critically ill: unique risk profile in a newly defined population. Crit Care Clin 2002; 18: 529-52.
27. Murphey ED, Fang G, Sherwood ER. Endotoxin pretreatment improves bacterial clearance and decreases mortality in mice challenged with Staphylococcus aureus. Shock 2008; 29: 512-8.
28. Torgersen C, Moser P, Luckner G, et al. Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis. Anesth Analg 2009; 108: 1841-7.
29. Kaukonen KM, Bailey M, Pilcher D, et al. Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med 2015; 372: 1629-38.
30. Yende S, D’Angelo G, Kellum JA, et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008; 177: 1242-7.
31. Opal SM, Fisher CJ, Dhainaut J-FA, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, doubleblind, placebo-controlled, multicenter trial. Crit Care Med 1997; 25: 1115-24.
32. Opal SM, Laterre P, Francois B, et al. Effect of eritoran, an antagonist of md2-tlr4, on mortality in patients with severe sepsis: the access randomized trial. JAMA 2013; 309: 1154-62.
33. Schefold JC. Immunostimulation using granulocyte- and granulocyte-macrophage colony stimulating factor in patients with severe sepsis and septic shock. Crit Care 2011; 15: 136.